

Medicare National Coverage Determination (NCD)

Topic: Medicare Coverage of Ocular Photodynamic Therapy (OPT) with Verteporfin for Macular Degeneration

Decision: Medicare will expand coverage of OCT for Macular Degeneration.

What this means: Effective for claims with dates of service on and after April 3, 2013, coverage will be expanded to include OPT with Verteporfin for “wet” age-related macular edema (AMD). Revisions were also made to the requirement for testing to permit either OCT or fluorescein angiography (FA) to assess treatment response.

For more information, contact Customer Service at the number listed on your ID card.

This announcement can be found at:

<http://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=349>

Effective date: April 3, 2013